Prefrontal Cortex and Abstract Thinking

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Institut National de la Santé Et de la Recherche Médicale, France
ClinicalTrials.gov Identifier:
NCT01100281
First received: April 7, 2010
Last updated: December 8, 2011
Last verified: December 2011
  Purpose

The capacity of concept formation is not well understood, even if a link is supposed with the functioning of the frontal lobes.

Our aim is to better understand the cognitive mechanisms underlying this function and to try to correlate the performance with atrophy of the frontal lobe in neurodegenerative diseases involving this region (frontotemporal lobar degeneration and progressive supranuclear palsy).


Condition Intervention
Abstract Thinking
Concept Formation
Behavioral: Neuropsychological examination
Other: MRI

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Neuropsychological and Anatomical Study of Concept Formation in Frontal Patients

Further study details as provided by Institut National de la Santé Et de la Recherche Médicale, France:

Enrollment: 69
Study Start Date: April 2010
Study Completion Date: April 2011
Groups/Cohorts Assigned Interventions
PSP (Progressive supranuclear palsy) Behavioral: Neuropsychological examination
Examination including especially concept formation
Other: MRI
MRI performed in T1-weighted three dimensional sequence
FTD (Frontotemporal lobar degenerative) Behavioral: Neuropsychological examination
Examination including especially concept formation
Other: MRI
MRI performed in T1-weighted three dimensional sequence
Alzheimer's disease Behavioral: Neuropsychological examination
Examination including especially concept formation
Other: MRI
MRI performed in T1-weighted three dimensional sequence

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

3 groups including : PSP, FTD, AD

Criteria

Inclusion Criteria:

  • informed consent signed
  • MMSE> 20
  • No contra indication to MRI

Exclusion Criteria:

  • MMSE<20
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01100281

Locations
France
Inserm U 975
Paris, France, 75013
Sponsors and Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
Investigators
Study Director: Richard Levy, MD Institut National de la Santé Et de la Recherche Médicale, France
  More Information

No publications provided

Responsible Party: Institut National de la Santé Et de la Recherche Médicale, France
ClinicalTrials.gov Identifier: NCT01100281     History of Changes
Other Study ID Numbers: C09-29
Study First Received: April 7, 2010
Last Updated: December 8, 2011
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Institut National de la Santé Et de la Recherche Médicale, France:
prefrontal cortex

ClinicalTrials.gov processed this record on July 20, 2014